Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Revista Brasileira de Hematologia e Hemoterapia

Volumn 34, Issue 5, 2012, Pages 352-355

  Petrola, Maria Juracy ^a   de Castro, Alana Joselina Montenegro ^a   Pitombeira, Maria Helena da Silva ^a   Barbosa, Maritza Cavalcante ^a   Quixadá, Acy Telles de Souza ^b   Duarte, Fernando Barroso ^a   Gonçalves, Romelia Pinheiro ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Hospital Universitário Walter Cantídio HUWC Fortaleza   (Brazil)

Author keywords

BCR ABL positive; Chronic; Leukemia; Malondialdehyde; Myelogenous; Oxidative stress; Protein tyrosine kinases

Indexed keywords

EID: 84869047969     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20120091     Document Type: Article

References (41)

1. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Sciences. 1986;233(4760):212-4.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 gene of the Philadelphia chromosome. Science. 1990;247(4944):824-30.
3. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18(3):569-84.
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Research. 1996;56(1):100-4.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-7. Comment in: N Engl J Med. 2001; 344(14):1084-6; N Engl J Med. 2001;345(8):618-9.
6. Funke VA, Setubal DC, Ruiz J, Azambuja AP, Lima DH, Kojo TK, et al. O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe. Rev Bras Hematol Hemoter. 2008;30(suppl.1):27-31.
7. An X, Tiwaria AK, Suna Y, Dinga PR, Ashby-Jr CR, Chena ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255-68.
8. Deininger WN. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw. 2005;3(6):757-68.
9. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-51. Comment in: J Clin Oncol. 2010;28(18):e310; author reply e311.
10. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-amino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-61.
11. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-5.
12. Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene. 2007;26(1):11-20.
13. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195-214.
14. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemias? Blood. 2011;117(22):5816-26.
15. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190-6.
16. Burke BA, Carroll M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogenous leukemia. Leukemia. 2010;24(6):1105-12.
17. nd ed. Lyon: WHO Press; 2008. 439 p. (IARC WHO Classification of Tumours).
18. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421-31.
19. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem. 1982;126(1):131-8.
20. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian, H. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-72.
21. Bortolheiro TC, Chiattone CS. Leucemia mielóide crônica: história natural e classificação. Rev Bras Hematol. Hemoter. 2008;30(1):3-7.
22. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol. 2009;22(3):295-302.
23. Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. Chronic myeloid leukemia. Lancet. 2007;370(9584):342-50. Comment in: Lancet. 2007;370(9593):1127.
24. Deshmukh C, Saikia T, Baksi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: a prospective single arm. Non-randomized study. J Assoc Physicians India. 2005;53:291-5.
25. Syed NN, Usman M, Khaliq G, Adil SN, Khurshid M. Clinico-pathologic features of chronic myeloid leukemia and risk stratification according to Sokal score. J. Coll Physicians Surg Pak. 2006;16(5):336-9.
26. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-99.
27. Campos MG, Arantes AM, Oliveira JSR, Chauffaille ML. Chronic myeloid leukemia: a disease of youth in Brazil. Leuk Res. 2010;34(4):542-4.
28. Cerutti PA. Pro-oxidant status and tumor promotion. Science. 1985;227(4685):375-81.
29. Ahmad R, Anil KT, Payal T, Ranjana S, Sushma S, Raj KS. Oxidative stress and antioxidant status in patients with chronic myeloid leukemia. Ind J Clin Biochem. 2008; 23(4):328-33.
30. Ahmad R, Tripathi AK, Tripathi P, Singh S, Singh R, Singh RK. Malondialdehyde and protein carbonyl as biomarkers for oxidative stress and disease progression in patients with chronic myeloid leukemia. In Vivo [Internet]. 2008 [cited 2010 Jun 21];22(4):525-8. Available from: http://iv.iiarjournals.org/content/22/4/525.long
31. Ciarcia R, D'angelo D, Pacilio C, Pagnini D, Galdiero M, Fiorito F, et al. Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells. J Cell Physiol. 2010;224(2):443-53.
32. Devi GS, Prasad MH, Saraswathi I, Raghu D, Rao DN, Reddy PP. Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias. Clin Chim Acta. 2000;293(1-2):53-62.
33. Oltra AM, Carbonell F, Tormos C, Iradi A, Guillermo T, Saez GT. Antioxidant enzyme activities and the production of MDA and 8-oxo-dg in chronic lymphocytic leukemia. Free Radic Biol Med. 2001;30(11):1286-92.
34. Battisti V, Madersa LD, Bagatinia MD, Santos KF, Spanevello RM, Maldonado PA, et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem. 2008;41(7-8):511-8.
35. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood [Internet]. 2003[cited 2011 Jan 23];101(10):4098-104. http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=12531810
36. Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol. 2009; 22(3):303-13.
37. Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S; Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). Tyrosine kinase inhibitors. Curr Cancer Drug Targets. 2010;10(5):462-83.
38. La Rosée P, Deininger MW Resistance to imatinib: mutations and beyond. Semin Hematol. 2010;47(4):335-43.
39. Delamain MT, Conchon M. Os inibidores de tirosino quinase de segunda geração. Rev Bras Hematol Hemoter. 2008;30(suppl.1):37-40.
40. Slupphaug G, Kavli B, Krokan HE. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res. 2003;531(1-2):231-51.
41. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood [Internet]. 2006 [cited 2011 Jan 21];108(1):319-27. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895841